References
- Viale G. Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment. Breast18(Suppl. 3), S32–S36 (2009).
- Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs20, 851–855 (2009).
- Magné N, Chargari C, Conforti R et al. Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future. Bull. Cancer97, 385–395 (2010).
- Magné N, Chargari C, Macdermed D et al. Tomorrow’s targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity ? Crit. Rev. Oncol. Hematol. (2010) (Epub ahead of print).
- Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol.27, 5924–5930, (2009).
- Mitsudomi T. Advances in target therapy for lung cancer. Jpn. J. Clin. Oncol.40, 101–106 (2010).
- Reynolds C, Obasaju C, Schell MJ et al. Randomized Phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J. Clin. Oncol.27, 5808–5815 (2009).
- Piette F, Spano JP, Chaibi P et al. Geriatric oncology: review of the epidemiologically obvious. Presse Med.39, 208–215 (2010).